Commentary: Mesothelioma … moving the needle on locoregional control has invited aggressive treatment options for limited distant metastases

Our plain-English summary of Commentary: Mesothelioma … moving the needle on locoregional control has invited aggressive treatment options for limited distant metastases, by M. Lanuti (JTCVS Techniques, 2020).

The study

• Author: M. Lanuti
• Journal: JTCVS Techniques
• Published: 2020;3:363-364
• Type of article: Editorial
• Read it: PubMed · Publisher · Free full text

In plain English

This is a short commentary, not a new study. The author discussed a case report by Li and colleagues, in the same issue, about one patient with epithelioid mesothelioma who developed a single brain metastasis 2 years after initial treatment. The patient had received radical pleurectomy and decortication with heated chemotherapy during surgery, followed by 4 cycles of chemotherapy. No cancer was found to have returned in the chest. Neurologic symptoms led to a brain scan showing a 2.4-cm frontal lobe tumor, which was removed surgically; stereotactic (focused) radiotherapy to the surgical bed followed. The patient was then disease free for an additional 3.5 years. The author noted that after aggressive combined treatment, distant spread has been less common than return near the original site. The author noted that Li and colleagues acknowledged sarcomatoid mesothelioma has more often been linked to brain spread than epithelioid mesothelioma, and that major guidelines give no recommendations for brain imaging. The author concluded that as local treatment improves, distant spread could become more common and aggressive treatment of limited metastases might be warranted. The commentary did not discuss asbestos exposure.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Commentary on a case report published in the same issue (Li and colleagues); not original research
• Who was studied: No study population of its own. It discusses one patient, reported by Li and colleagues, with epithelioid mesothelioma who had a brain metastasis 2 years after initial treatment.
• Main results:
  • The author stated that after aggressive multimodality therapy for mesothelioma, distant sites of failure have been less common than locoregional recurrence.
  • The author stated that earlier case reports of mesothelioma spreading to the brain, dating back to 1995, highlighted aggressive local therapy with limited long-term survival.
  • In the patient reported by Li and colleagues, brain imaging prompted by neurologic symptoms found a 2.4-cm frontal lobe metastasis.
  • That patient was treated with craniotomy and resection, followed by stereotactic radiotherapy to the surgical bed, and was then disease free for an additional 3.5 years.
  • The author noted that Li and colleagues acknowledged that sarcomatoid mesothelioma has been more often associated with brain metastasis than epithelioid mesothelioma.
  • The author noted that surveillance strategies for mesothelioma are not well addressed in major guidelines and that no recommendations for brain imaging are available.
• The authors' conclusion: The author concluded that as local therapy improves, distant metastases could become more prevalent, and aggressive local options for limited (oligometastatic) disease might be warranted. The author added that patient selection is paramount and that the challenges will be best managed at centers of excellence.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• Invited commentary: Is it possible to investigate the quantitative relation between asbestos and mesothelioma in a community-based study? — J. Siemiatycki, P. Boffetta (1998)
• Invited commentary — R.M. Flores (2014)
• Invited commentary — B.C. Tong (2014)
• Invited commentary — L. Lang-Lazdunski (2015)
• Invited commentary — V.W. Rusch (2015)
• Invited Commentary — B.M. Burt (2015)

Browse return to medical research.